Gene · 5598
Papers3,971
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,971
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. | Antioxid Redox Signal | 2025 | 40183134 | PubTator, text mining | PubMed |
| The relationship between MAPK signaling pathways and osteogenic differentiation of periodontal ligament stem cells: a literature review. | PeerJ | 2025 | 40183050 | PubTator, text mining | PubMed |
| Shear Wave Elastography: A Non-Invasive Approach for Assessing TGF-β1/MAPK Signaling Molecules and EMT in Breast Cancer. | Breast Cancer (Dove Med Press) | 2025 | 40160304 | PubTator, text mining | PubMed |
| [Study on the mechanism of apoptosis mediated by acid sensitive ion channel 1 through extracellular signal regulation of kinase 5 signaling pathway and mitochondrial disorder pathway]. | Zhongguo Gu Shang | 2025 | 40148093 | PubTator, text mining | PubMed |
| Mapk7 enhances osteogenesis and suppresses adipogenesis by activating Lrp6/β-catenin signaling axis in mesenchymal stem cells. | Commun Biol | 2025 | 40000807 | PubTator, text mining | PubMed |
| A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy. | Signal Transduct Target Ther | 2025 | 39979271 | PubTator, text mining | PubMed |
| MEK5-ERK5 pathway mediates mitophagy by regulating Nur77 to promote tumorigenesis of osteosarcoma cells. | Eur J Med Res | 2025 | 39972514 | PubTator, text mining | PubMed |
| The effect of low energy LED red light on osteogenetic differentiation of periodontal ligament stem cell via the ERK5 signal pathway. | Lasers Med Sci | 2025 | 39873791 | PubTator, text mining | PubMed |
| Investigation of Aframomum melegueta compounds as ERK5 inhibitor related to breast cancer via molecular docking and dynamic simulation. | In Silico Pharmacol | 2025 | 39872469 | PubTator, text mining | PubMed |
| MicroRNA Gets a Mighty Award. | Adv Sci (Weinh) | 2025 | 39836690 | PubTator, text mining | PubMed |
| Toona sinensis fruit polyphenols alleviate cerebral ischemia-reperfusion injury in rats by inhibiting MAPK signaling pathways and NLRP3 inflammasome/pyroptosis. | J Ethnopharmacol | 2025 | 39828145 | PubTator, text mining | PubMed |
| Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer. | ACS Med Chem Lett | 2025 | 39811115 | PubTator, text mining | PubMed |
| Suppression of KLF5 targets RREB1 to restrain the proliferation of ovarian cancer cells through ERK/MAPK signaling pathway. | 3 Biotech | 2025 | 39676889 | PubTator, text mining | PubMed |
| TXN promotes tumorigenesis by activating the ERK1/2 and ERK5 signaling pathways regulating c-Myc in non-small cell lung cancer. | Cell Signal | 2025 | 39571701 | PubTator, text mining | PubMed |
| Resveratrol and ceftriaxone encapsulated in hybrid nanoparticles to prevent dopaminergic neurons from degeneration for Parkinson's disease treatment. | Biomater Adv | 2025 | 39426178 | PubTator, text mining | PubMed |
| Trehalose Prevents IL-4/IL-13-Induced Skin Barrier Impairment by Suppressing IL-33 Expression and Increasing NRF2 Activation in Human Keratinocytes In Vitro. | J Invest Dermatol | 2025 | 39384017 | PubTator, text mining | PubMed |
| Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions. | Physiol Rev | 2025 | 39115424 | PubTator, text mining | PubMed |
| Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. | Mol Oncol | 2025 | 38965815 | PubTator, text mining | PubMed |
| Impinging Flow Mediates Vascular Endothelial Cell Injury through the PKCα/ERK/PPARγ Pathway in vitro. | Cerebrovasc Dis | 2025 | 38688248 | PubTator, text mining | PubMed |
| Function of formyl peptide receptor 2 in adriamycin resistance of breast cancer. | Exp Biol Med (Maywood) | 2024 | 39881881 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5598/papers?page=6